• 1. 研究生，現(xiàn)在川北醫(yī)學(xué)院附院普外科(南充637007)2. 華西醫(yī)科大學(xué)附屬第一醫(yī)院普外科3. 四川省人民醫(yī)院普外科;

用LSAB免疫組織化學(xué)法檢測245例乳腺癌石蠟標(biāo)本C-erb B-2癌基因的表達(dá)。結(jié)果顯示：該癌基因的過度表達(dá)與乳腺癌的臨床分期晚、組織學(xué)分級高、腋窩淋巴結(jié)有轉(zhuǎn)移、雌、孕激素受體缺乏及預(yù)后差有關(guān)。該癌基因的表達(dá)是乳腺癌中腋淋巴結(jié)狀況之外的又一個獨(dú)立預(yù)后因素。該基因表達(dá)的檢測作為乳腺癌常規(guī)病理檢查，可用于判斷乳腺癌的預(yù)后及擬定術(shù)后治療方案。

引用本文： 幸天勇,楊金巧,周蕾蕾. 乳腺癌C-erb B-2癌基因與雌、孕激素受體的關(guān)系及預(yù)后意義. 中國普外基礎(chǔ)與臨床雜志, 1999, 6(1): 21-23. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. 姚先瑩. 乳腺疾病激素受體的研究小結(jié). 四川醫(yī)學(xué)， 1981； 2(1)∶69.
2. Porter PL, Garcia R, Moe R, et al. Cerb B2 oncogene protein in situ and invasive lobular breast neoplasia. Cancer, 1991; 68(2)∶331.
3. Allred DC, Clark GM, Molina R, et al. Overexpression of Her2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 1992; 23(9)∶947.
4. Zhou D, Dattifora H, Yokota J, et al. Association of multiple copies of the Cerb B2 oncogene with spread of breast cancer. Cancer Res, 1987; 47(22)∶6123.
5. May E, Mouriesse H, MayLevin F, et al. Human breast cancer: identification of populations with a high risk of early relapse in relation to both estrogen receptor status and Cerb B2 overexpression. Br J Cancer, 1990; 62(3)∶430.
6. Richard M, Elledge MD, Daniel R, et al. Estrogen receptor, progesteroner receptor and HER 2/neu protein in breast cancers from pregnancy patients. Cancer, 1993; 71(8)∶2499.
7. Wright C, Niebolson S, Angus B, et al. Relationship between Cerb B2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer, 1992; 65(1)∶118.
8. Borg A, Tandon AK, Sigurdsson H, et al. Her2/neu amplification predicts poor survival in nodepositive breast cancer.Cancer Res, 1990; 50(14)∶4332.
  1. 1. 姚先瑩. 乳腺疾病激素受體的研究小結(jié). 四川醫(yī)學(xué)， 1981； 2(1)∶69.
  2. 2. Porter PL, Garcia R, Moe R, et al. Cerb B2 oncogene protein in situ and invasive lobular breast neoplasia. Cancer, 1991; 68(2)∶331.
  3. 3. Allred DC, Clark GM, Molina R, et al. Overexpression of Her2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 1992; 23(9)∶947.
  4. 4. Zhou D, Dattifora H, Yokota J, et al. Association of multiple copies of the Cerb B2 oncogene with spread of breast cancer. Cancer Res, 1987; 47(22)∶6123.
  5. 5. May E, Mouriesse H, MayLevin F, et al. Human breast cancer: identification of populations with a high risk of early relapse in relation to both estrogen receptor status and Cerb B2 overexpression. Br J Cancer, 1990; 62(3)∶430.
  6. 6. Richard M, Elledge MD, Daniel R, et al. Estrogen receptor, progesteroner receptor and HER 2/neu protein in breast cancers from pregnancy patients. Cancer, 1993; 71(8)∶2499.
  7. 7. Wright C, Niebolson S, Angus B, et al. Relationship between Cerb B2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer, 1992; 65(1)∶118.
  8. 8. Borg A, Tandon AK, Sigurdsson H, et al. Her2/neu amplification predicts poor survival in nodepositive breast cancer.Cancer Res, 1990; 50(14)∶4332.